

RECEIVED
CENTRAL FAX CENTER

FEB 25 2005


PTO/SB/21 (04-04)


Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after Int'l filing)</i>		Application Number 10/787,385
Total Number of Pages in This Submission	4	Filing Date 2/26/04
		Inventor Steven C. Quay et al.
		Art Unit 1623
		Examiner Name
		Attorney Docket Number 03-02US

ENCLOSURES <i>(Check all that apply)</i>		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached \$65 <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> Request to Correct Priority Claim <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Substitute Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Declaration and Power of Attorney, Declaration, 2 pages <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Substitute page one of form 1449A/PTO
Remarks <p>We recently filed an IDS of 3 pages with references on 1/14/2005. We noted a typographical error on page 1. The Mayor Pharmaceutical Laboratories US patent number has been corrected from 4,523,341 to the correct patent number of 4,525,341. Kindly switch out the prior page one of form 1449A/PTO for this new page one. Thank you.</p>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Nastech Pharmaceutical Company Inc., Paul G. Lunn, Attorney, Registration No. 32,743
Signature	
Date	February 25, 2005

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO to the Fax number 703-872-9306 on the date shown below.	
Typed or printed name	Jeffrey L. Granger
Signature	
	Date February 25, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FEB 25 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Quay et al.	Attorney Docket No.: 03-02US
Serial No.: 10/787,385	Group Art Unit: 1623
Filed: 2/26/2004	Examiner: unknown
Title: CYANOCOBALAMIN LOW VISCOSITY AQUEOUS FORMULATIONS FOR INTRANASAL DELIVERY	

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

SUBSTITUTE INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

- under 37 CFR 1.97(b), or
 (Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
- under 37 CFR 1.97(c) together with either a:
 — Statement under 37 CFR 1.97(e), or
 — a \$180.00 fee under 37 CFR 1.17(p), or
 (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- under 37 CFR 1.97(d) together with a:
 — Statement under 37 CFR 1.97(e), and
 — a \$180.00 fee set forth in 37 CFR 1.17(p).
 (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Applicant(s) submit herewith a substitute Form PTO 1449-Information Disclosure Citation page one only.

Applicants also wish to bring to the attention of the Examiner that the assignee previously prosecuted patent application no. 06/723,859, entitled "Aerosol Compositions for Nasal Delivery of Vitamin B12," filed April 16, 1985, which was abandoned by the assignee.

The relevance of the attached references is that this is the closest art of which Applicant is aware. Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

I hereby certify that this Correspondence is being facsimile transmitted to the USPTO at fax number 703-872-9306, on the date indicated below.

Date of Deposit: February 25, 2005

Typed Name: Jeffrey L. Granger

Signature:



Respectfully submitted,



Paul G. Lunn
Attorney/Agent for Applicant(s)
Reg. No. 32743

Date: February 25, 2005

Telephone No.: (425) 908-3643

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

3

Attorney Docket Number 03-02US

Complete If Known

Application Number	10787,385
Filing Date	2/26/2004
First Named Inventor	Quay et al.
Art Unit	1623
Examiner Name	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Issued Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)	MM-DD-YYYY		
		US- 2,703,302	03-01-1955	Merck & Co., Inc.	
		US- 2,703,303	03-01-1955	Merck & Co., Inc.	
		US- 2,746,796	05-22-1958	The Pharma-Craft Corporation	
		US- 2,914,222	11-24-1959	Philip Mashberg	
		US- 3,000,783	09-19-1961	Merck & Co., Inc.	
		US- 2,951,017	08-30-1960	The Distillers Company Limited	
		US- 3,057,851	10-09-1962	Armour Pharmaceutical	
		US- 3,018,225	01-28-1962	Merck & Co., Inc.	
		US- 3,120,508	02-04-1964	Hoffmann-La Roche Inc.	
		US- 3,282,781	11-01-1968	Merck & Co., Inc.	
		US- 3,548,057	12-15-1970	Merck & Co., Inc.	
		US- 3,577,537	05-04-1971	Merck & Co., Inc.	
		US- 3,584,115	06-08-1971	Arthur I. Gobart & Angelo T. Bandura	
		US- 3,857,966	05-18-1976	GAF Corporation	
		US- 4,174,285	11-13-1979	Mentadien S.p.A.	
		US- 4,525,341	08-25-1985	Mayor Pharmaceutical Laboratories	
		US- 4,724,231	02-09-1988	Nastech Pharmaceutical, Inc.	
		US- 5,801,161	09-01-1998	Merkus, Prandicus	
		US- 5,797,390	08-25-1998	McSoley, Thomas E.	
		US- 5,825,625	07-20-1999	Merkus, Prandicus	
		US- 6,665,421	12-16-2003	Image Therm Engineering, Inc.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document	Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		EP 0131315 A2	02-15-1984	Istituto De Angelis		
		EP 0130550 A2	05-27-1984	Instermedical GmbH		
		PCT WO 88/05988 (International Application Number PCT/US88/00793)	10-23-1988 Publication Date	Nastech Pharmaceutical Company, Inc.		
		PCT WO 88/05987 (International Application Number PCT/US88/00665)	10-23-1988 Publication Date	Nastech Pharmaceutical Company, Inc.		

Examiner Signature	Data Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁵Kind of document by Translator is attached.

This collection of information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments and suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.